Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2022-02-16 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing Classification · 100% confidence The document explicitly begins with "**FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**" and is titled "**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**". Form 4 filings are used by corporate insiders (directors, officers, or 10% owners) to report transactions in the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades). Although the document discusses transactions, it is a specific regulatory filing (Form 4) detailing insider trades, which maps precisely to the 'Director's Dealing' category (DIRS). It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory announcement (RNS), as it serves a very specific disclosure purpose.
2022-02-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Regulatory Filings Classification · 95% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key indicator is the line: "Attached hereto is a report on *Form 4A*" followed by a filename. Form 4A is typically an amendment or a specific report filed with the SEC, often related to insider transactions or specific corporate events, but in this context, it is being filed as an 'Other Report or Announcement' under Israeli regulations (Regulation 5 of the Securities Regulations). Since the document itself is very short (1860 chars) and explicitly states that another report (*Form 4A*) is attached or referenced, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS) announcing the availability of another document, rather than being the full content of that report. Given the specific nature of the attachment (Form 4A, which often relates to insider trading or specific corporate actions), and the lack of a direct match for 'Form 4A' in the provided definitions, RNS (Regulatory Filings - general fallback) is appropriate, although RPA is also plausible if this is just an announcement wrapper. However, since it is a formal regulatory filing announcement referencing a specific form (Form 4A), RNS is the most robust classification for miscellaneous regulatory announcements not covered elsewhere.
2022-02-16 English
Director's Dealing 2022
Director's Dealing
2022-02-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RAKIN KEVIN
Director's Dealing Classification · 100% confidence The document explicitly begins with the header "SEC Form 4" and the title "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP". Form 4 is the standard SEC filing used to report insider transactions (changes in beneficial ownership) by directors, officers, and 10% owners of a company. This directly corresponds to the definition of Director's Dealing (insider trades). Although the document text is structured like a regulatory filing, the specific nature of Form 4 points directly to the 'DIRS' category, which covers 'Report of personal share transactions by company directors and executives (insider trades)'.
2022-02-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RAKIN KEVIN
Director's Dealing Classification · 98% confidence The document explicitly states it is an 'Other Report or Announcement' filed under 'Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000'. Crucially, it mentions an attached document: '*Form 4*'. Form 4 filings in the US context (indicated by the NASDAQ listing and US address) are used to report insider transactions (changes in beneficial ownership by directors, officers, or 10% owners). Reviewing the provided definitions: - 10-K is the Annual Report. - ER is the Earnings Release. - IR is the Interim Report. - DEF 14A is Remuneration Information. - DIRS is Director's Dealing (insider trades). Form 4 directly corresponds to reporting personal share transactions by company directors and executives, which matches the definition for 'Director's Dealing' (Code: DIRS). Although the document is an announcement referencing the Form 4, the core subject matter is the insider transaction report itself. Given the specific nature of Form 4, DIRS is a more precise classification than the general 'RPA' or 'RNS', especially since the content strongly implies the nature of the filing (insider transaction disclosure). The document length (1861 chars) is short, but it is reporting the filing of a specific regulatory form (Form 4) which is the subject of the DIRS category.
2022-02-15 English
Director's Dealing 2022
Director's Dealing
2022-02-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.